相似文献
1
Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm.
J Clin Oncol. 2008 Oct 1;26(28):4693-4; author reply 4694-5. doi: 10.1200/JCO.2008.18.8060.
2
Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
Clin Colorectal Cancer. 2008 Jul;7(4):226. doi: 10.3816/CCC.2008.n.030.
3
[Metastatic colorectal cancer: adjournments from ESMO 2006].
Tumori. 2006 Nov-Dec;92(6):1-12. doi: 10.1177/030089160609200627.
4
Current role of bevacizumab in colorectal cancer.
Clin Adv Hematol Oncol. 2009 Jun;7(6):375-6.
5
Common side effects and interactions of colorectal cancer therapeutic agents.
J Pract Nurs. 2011 Spring;61(1):7-20.
6
Chemotherapy and immunotherapy in metastatic colorectal cancer.
N Engl J Med. 2009 May 14;360(20):2134; author reply 2135-6. doi: 10.1056/NEJMc090489.
7
Chemotherapy and immunotherapy in metastatic colorectal cancer.
N Engl J Med. 2009 May 14;360(20):2135; author reply 2135-6.
8
Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008.
Clin Colorectal Cancer. 2008 Jul;7(4):233-9. doi: 10.1016/s1533-0028(11)70426-1.
9
Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
J Clin Oncol. 2007 Sep 20;25(27):4165-7. doi: 10.1200/JCO.2007.11.6582. Epub 2007 Aug 20.
10
Update on capecitabine alone and in combination regimens in colorectal cancer patients.
Cancer Treat Rev. 2010 Nov;36 Suppl 3:S46-55. doi: 10.1016/S0305-7372(10)70020-7.
Zotero 插件